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EDITORIAL
Inactive  Carriers  of  Hepatitis  B Virus:  A  Never  Ending
Story
Portadores  Inativos  do  Vírus  da  Hepatite  B:  Uma  História  Interminável
Guilherme MacedoGastroenterology  Department,  Centro  Hospitalar  de  São  João,  Porto,  Portugal
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bThe  so-called  inactive  carriers  are  regularly  revisited  in
hepatologist’s  literature,  but  many  pending  issues  are  yet
unsolved.  Magalhães  et  al  looked  back  in  to  a  cohort  of
patients  carefully  followed  with  serial  assessment  of  some
blood  parameters,  trying  to  indirectly  validate  their  own
strategy  of  monitoring.
Patients  infected  with  hepatitis  B  virus  (HBV)  present  sev-
eral  patterns  of  serological  markers  and  viral  activity.  When
adopting  viremia  as  an  indicator  of  HBV  replication,  sub-
sets  of  patients  may  be  deﬁned:  HBs  Ag  positive  patients
with  persistent  and  on-going  viral  replication;  Hbs  Ag  pos-
itive  patients  with  permanent  or  temporary  inhibition  of
viral  replication:  this  is  a  highly  heterogeneous  group  and
included  coinfected  patients  with  HDV,  HCV,  inactive  carri-
ers  and  patients  with  ﬂuctuating  viral  load  levels  detectable
with  more  sensitive  HBV  DNA  assays.
It  is  also  known  that  although  HBV  is  not  cytopathogenic,
patients  with  chronic  HBV  infection  have  a  signiﬁcant  risk
of  developing  severe  liver  diseases.  During  the  natural
course  of  chronic  hepatitis  B  virus  (CHB)  infection,  different
immune  phases  have  identiﬁed  as  immune  tolerant  phase,
immune  clearance  (or  immuneactive,  phase,  low  replicative
phase  and  asymptomatic  chronic  carrier  state).
The  low  replication  phase,  being  referred  as  the  inactive
HBsAg  carrier  state,  occurs  after  HBeAg  seroconversion  and
is  usually  characterized  with  a  marked  reduction  or  unde-
tectable  level  of  serum  HBV  DNA,  ALT  normalization  andE-mail address: guilhermemacedo59@gmail.com
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tate  may  last  a  lifetime,  but  proportion  of  patients  may
ndergo  subsequent  spontaneous  or  immunosuppression-
nduced  of  HBV  replication  generally  referred  as  relapse.
he  CHB  patients  with  a  relapse  often  exhibit  reappear-
nce  of  high  levels  of  serum  HBV,  ALT  abnormalization
nd  reversal  of  HBeAg  seroreversion.  It  is  important  to
istinguish  between  inactive  carriers  and  individuals  with
BeAg-negative  CHB,  because  the  form  has  been  carried  to
ave  a  favourable  long-term  outcome,  whilst  the  latter  is
ess  responsive  treatment  and  associated  with  progressive
iver  disease.
Another  very  important  issue  is  that  if  inactive  carri-
rs  are  not  followed,  they  might  be  engaged  in  any  sort  of
mmunosuppressive  therapy,  not  easily  recognized  by  other
pecialists,  which  may  introduce  a  signiﬁcant  risk  factor  for
eactivation.  Reactivation  of  hepatitis  B  is  a rare  but  dis-
inctive  syndrome  deﬁned  by  an  abrupt,  marked  increase
n  HBV  replication  usually  accompanied  by  elevations  in
erum  aminotransferase  levels  and  sometimes  by  jaundice.
eactivation  of  HBV  can  occur  spontaneously  but  is  more
ommon  in  the  setting  of  immune  suppression  or  cancer
hemotherapy.
Even  with  these  risks  to  follow  up  strategy  for  inac-
ive  carriers  have  been  very  disputed  reﬂecting  the  need
f  a  precise  knowledge  of  the  replicative  phase  and  the
aseline  histology  of  the  liver.  We  and  others  have  looked
n  to  the  histology  of  inactive  carriers  and  found  out
hat  cirrhosis  featured  in  12%  of  these  patients;  and  that
he  overall  burden  of  inactive  carriers  within  the  chronic
dade Portuguesa de Gastrenterologia. This is an open access article
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epatitis  B  population  was  not  higher  than  23%  stressing  the
act  that  many  of  these  ‘‘quiet’’  individuals  were  indeed
hronic  HBeAg  negative  hepatitis  patients.
The  paper  from  Magalhães  et  al  has  an  interesting  mean
ollow  up  period  (4.6  years),  in  which  transient  elevation  of
LT  was  surprisingly  rare  and  liver  biopsies  were  available
nly  in  a  minority  of  patients.  These  facts  of  course  preclude
ny  deﬁnitive  assumption  of  a  favourable  progression  of  the
atients,  but  acknowledged  the  need  of  regular  assessment
ith  biochemical  and  with  virological  activity.  Concerning
he  recent  data  on  the  role  of  HBsAg  quantiﬁcation  for  mon-
toring  natural  history,  including  the  recognized  issue  that  in
atients  with  chronic  HBV  infections,  a  high  HBsAg  level  was
ssociated  with  an  increased  risk  of  HCC  and  was  an  indepen-
ent  risk  factor  for  HCC  in  those  with  a  low  HBV  viral  load  this
ould  stand  as  an  additional  strategy  to  be  implemented.
he  rational  for  its  implementation  relies  on  the  fact  that
iral  proteins  of  clinical  importance  include  the  envelope
rotein  (HBsAg)  whose  synthesis  during  the  HBV  viral  life
ycle  is  complex.  HBsAg  production  exceeds  that  required
or  virion  assembly,  and  excess  surface  envelope  proteins
re  covalently  linked  secreted  as  empty  non-infections  ﬁla-
entous  or  spherical  sub-viral  particles.
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These  empty  particles  may  co-exist  with  anti  HBs  as  part
f  circulating  immune  complexes.
Serum  HBsAg  is  a  result  of  the  combination  of  these  pro-
eins  (complete  virion,  ﬁlamentous  or  spherical  sub-viral
articles).  HBsAg  quantiﬁcation  measures  all  three  forms  of
ystemic  HBsAg.
The  combination  of  a single  measurement  of  HBsAg  less
han  1000  IU/ml  and  HBV  DNA  less  than  2000  IU/ml  identi-
es  ‘‘inactive  carries’’  with  a  PPV  of  86%.  More  recently,  the
uthors  in  this  French  study  reported  that  the  combination
f  single  measurement  of  HBsAg  above  1000  IU/ml  and  HBV
NA  above  200  IU/ml  identiﬁes  patients  with  a  ‘‘high  risk  of
eactivation’’  with  a  negative  predictive  value  (NPV)  of  96%,
nd  sensitivity  92%.  The  authors  conclude  that  combination
f  HBsAg  and  HBV  DNA  levels  at  a  single  time  point  may
ccurately  identify  HBeAg  (−) CHB  patients,  during  remis-
ion  with  a  high  probability  of  reactivation  and  who  are  good
andidates  for  treatment.
In  conclusion,  no  ﬁnal  word  has  yet  to  be  proclaimed.  It is
easonable  to  follow  up  these  patients,  thoroughly,  with  reg-
lar  ALT  and  DNA  assessment,  eventually  also  proﬁling  HBsAg
evels,  so  that  prompt  recognition  of  trouble  is  warranted  in
 presumed  benign  and  stable  condition.
